Mirati Therapeutics Inc.
Clinical trials sponsored by Mirati Therapeutics Inc., explained in plain language.
Now part of
Bristol-Myers Squibb Company
BMY
NYSE
Oncology biotech focused on targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a cancer drug be tailored for japanese patients? a new trial seeks answers Results expected Sep 2026 (estimated)
- New drug cocktail targets Hard-to-Treat lung cancer mutation Results expected Sep 2026 (estimated)
- Lung cancer drug adagrasib: which dose works best? Results expected Oct 2026 (estimated)